Book contents
- Consumer Genetic Technologies
- Consumer Genetic Technologies
- Copyright page
- Contents
- Contributors
- Acknowledgments
- Introduction
- Part I Consumer Genetic Technologies: Rights, Liabilities, and Other Obligations
- Part II Privacy in the Age of Consumer Genetics
- Part III Tinkering with Ourselves: The Law and Ethics of DIY Genomics
- Part IV Consumer Genetics and Identity
- Part V The Impact of Genetic Information
- Introduction to Part V
- 17 An Ethical Framework for Genetic Counseling in the Genomic Era
- 18 Physician-Mediated Elective Whole Genome Sequencing Tests
- 19 Privacy Best Practices for Direct-to-Consumer Genetic Testing Services
- 20 Regulatory and Medical Aspects of DTC Genetic Testing
20 - Regulatory and Medical Aspects of DTC Genetic Testing
from Part V - The Impact of Genetic Information
Published online by Cambridge University Press: 27 August 2021
- Consumer Genetic Technologies
- Consumer Genetic Technologies
- Copyright page
- Contents
- Contributors
- Acknowledgments
- Introduction
- Part I Consumer Genetic Technologies: Rights, Liabilities, and Other Obligations
- Part II Privacy in the Age of Consumer Genetics
- Part III Tinkering with Ourselves: The Law and Ethics of DIY Genomics
- Part IV Consumer Genetics and Identity
- Part V The Impact of Genetic Information
- Introduction to Part V
- 17 An Ethical Framework for Genetic Counseling in the Genomic Era
- 18 Physician-Mediated Elective Whole Genome Sequencing Tests
- 19 Privacy Best Practices for Direct-to-Consumer Genetic Testing Services
- 20 Regulatory and Medical Aspects of DTC Genetic Testing
Summary
The recent FDA marketing authorizations granted for testing for mutations associated with hereditary breast and colon cancer, as well as pharmacogenomic susceptibilities, provide an opportunity to re-examine the medical as well as regulatory underpinnings of DTC genetic testing. In this chapter, we first examine the historical emergence of enabling technologies that have provided for the availability of DNA sequence information on a broad scale, the efforts by the medical community to incorporate these advances into models of “precision” or “personalized” medicine, and the risks and benefits of offering access to DNA germline sequence analysis outside of the traditional medical model. We then turn to the current and proposed regulatory schemes to provide oversight over DTC genetic testing, with a focus on the role of the FDA as an information regulator and guardian of public health and safety.
- Type
- Chapter
- Information
- Consumer Genetic TechnologiesEthical and Legal Considerations, pp. 277 - 292Publisher: Cambridge University PressPrint publication year: 2021
- 1
- Cited by